

1 **Co-Infections from Zika and Chikungunya Virus in Bahia, Brazil Identified by**
2 **Metagenomic Next-Generation Sequencing**

3

4 Silvia Sardi*¹, Sneha Somasekar*^{2,3}, Samia N. Naccache^{2,3}, Antonio Carlos Bandeira⁴,
5 Laura B. Tauro⁵, Gubio S. Campos¹, and Charles Y. Chiu^{2,3,6**}

6

7 Affiliations:

8 ¹Laboratory of Virology, Health Institute of Science, Federal University of Bahia,
9 Salvador, Bahia, Brazil

10 ²Department of Laboratory Medicine, University of California, San Francisco, CA 94107

11 ³UCSF-Abbott Viral Diagnostics and Discovery Center, San Francisco, CA 91407

12 ⁴Alianca Hospital, Salvador, Bahia, Brazil

13 ⁵Gonçalo Moniz Research Center - Oswaldo Cruz Foundation (FIOCRUZ), Salvador,
14 Bahia, Brazil

15 ⁶Department of Medicine, Division of Infectious Diseases, University of California, San
16 Francisco, CA 94107

17

18 *Co-first authors

19

20 ****Corresponding author:** Charles Chiu, MD/PhD, charles.chiu@ucsf.edu

21

22 **Keywords:** chikungunya virus, Bahia, Brazil, Zika virus, flaviviruses, co-infection,

23 mosquito-borne infections, emerging outbreaks, metagenomic next-generation

24 sequencing (mNGS), whole-genome assembly

25

27 Running Head: ZIKV and CHIKV Co-Infections

28

29 **ABSTRACT**

30 Metagenomic next-generation sequencing (mNGS) of 15 patients with
31 documented ZIKV infection in Bahia, Brazil from April 2015 to January 2016 identified
32 co-infections with chikungunya virus (CHIKV) in 2 of 15 ZIKV PCR-positive cases
33 (13.3%). While generally non-specific, the clinical presentation corresponding to these
34 two CHIKV/ZIKV co-infections reflected infection by the virus present at higher titer.
35 Aside from CHIKV and ZIKV, co-infections from other viral pathogens were not detected.
36 The mNGS approach is promising for differential diagnosis of acute febrile illness and
37 identification of co-infections, although targeted arbovirus screening may be sufficient in
38 the current ZIKV outbreak setting.

39

40 **INTRODUCTION**

41 Zika virus (ZIKV), a flavivirus, and chikungunya virus (CHIKV), an alphavirus, are
42 infectious RNA arboviruses transmitted to humans by the bite of *Aedes* spp. mosquitoes.
43 Both viruses have only recently emerged in the Western Hemisphere (1, 2), and along
44 with dengue virus (DENV), another flavivirus, now circulate widely in Brazil. The acute
45 illness caused by these viruses, characterized by fever, rash, myalgia, arthralgia, and
46 conjunctivitis, is non-specific, and differential diagnosis on the basis of clinical findings
47 alone is challenging. Later infectious sequelae include chronic arthritis for CHIKV (2) and
48 encephalitis, immune-mediated syndromes, and stroke for DENV (3). Recently, the
49 association between ZIKV infection and severe fetal complications such as microcephaly
50 in pregnant women has been established (4), and the virus has also been linked to
51 neurological complications such as Guillain-Barré syndrome (5). Thus, broad-based
52 assays are needed for differential diagnosis of vector-borne febrile illnesses and to

53 identify potential co-infections. Here we report the utility of metagenomic next-
54 generation sequencing (mNGS) as a screening tool to identify co-infections and for
55 genome recovery and phylogenetic analyses directly from patient serum samples in the
56 context of the ongoing ZIKV outbreak. We also show that the clinical presentation of
57 arboviral co-infections seems to favor the virus present at higher titer in acutely infected
58 individuals.

59

60 **MATERIALS AND METHODS**

61 **ZIKV serum sample collection, ZIKV RT-PCR, and DENV antibody testing.**

62 Written patient consent and ethics committee approval for this study were obtained
63 under CAAEV 45483115.0.0000.0046, number 1159.184, Brazil. Serum samples were
64 obtained from 15 patients seen at Aliança Hospital in Salvador, Bahia, Brazil from April
65 2015 to January 2016 who were given a presumptive diagnosis of an acute viral illness
66 by emergency department physicians and were found to be positive by qualitative RT-
67 PCR testing for ZIKV. Serum samples Bahia01 – Bahia15 were subjected to RNA
68 extraction using the QIAamp Viral RNA Mini Kit (Qiagen), and RNA was reverse
69 transcribed using the Superscript II Reverse Transcription Kit (Invitrogen), followed by
70 qualitative RT-PCR testing for ZIKV using primers targeting the NS5 gene (6). Serum
71 samples were also tested by DENV infection using an ELISA specific for the NS1
72 antigen and anti-DENV IgG/IgM according to the manufacturer's instructions (Dengue
73 Duo Test, Bioeasy Diagnostica, Brazil).

74 **Metagenomic next-generation sequencing.** A separate serum aliquot was
75 extracted for total nucleic acid using the Qiagen Viral RNA Mini Kit (Qiagen), followed by
76 DNase treatment using a cocktail of Turbo DNase (Thermo-Fischer Scientific and
77 Baseline-ZERO DNase Epicentre), followed by NGS construction using the NexteraXT
78 kit (Illumina) as previously described (7, 8). Two independent runs of single-end, 160

79 base pair (bp) dual-indexed barcoded mNGS libraries were performed on an Illumina
80 MiSeq instrument. To minimize flow cell cross-contamination during sequencing, a
81 known high-titer ZIKV PCR-positive sample was sequenced independently from the
82 other samples. The metagenomic data were scanned for any reads corresponding to
83 known pathogens using the SURPI (sequence-based ultra-rapid pathogen identification)
84 computational pipeline (9).

85 **Confirmatory CHIKV RT-PCR testing.** Confirmatory RT-PCR testing for
86 chikungunya virus was performed using a qualitative nested RT-PCR assay targeting the
87 E2 gene as previously described (10, 11). PCR primers and assay conditions were
88 identical to those outlined in (11) except for the substitution of 25 μ L master mix taken
89 from the Qiagen One-Step RT-PCR Kit (Qiagen). A presumptive ZIKV/CHIKV co-
90 infection identified by mNGS was considered established only if confirmed by positive
91 CHIKV RT-PCR testing from the original extract (10, 11).

92 **Determination of ZIKV titers.** To quantify ZIKV viremia, a standard curve was
93 established and repeat ZIKV PCR testing of the 15 patient serum samples performed
94 using a SYBR-Green quantitative RT-PCR (qRT-PCR) assay with primers targeting the
95 envelope gene (ZIKV-1086/ZIKV-1162) (12).

96 **DENV RT-PCR testing.** RNA testing for DENV of the 15 patient serum samples
97 was performed using a previously published nested RT-PCR assay (13). Both first-round
98 and second-round PCR amplicons were visualized by 2% agarose gel electrophoresis,
99 and bands of expected size were extracted from the gel and sequenced by Sanger
100 sequencing. DENV RT-PCR testing of the 15 serum samples in this study yielded only
101 one band in a single sample that was sequenced and found to correspond to *Aedes*
102 *aegyptii* mosquito genome.

103 **Capture probe enrichment.** To aid genome recovery of sample Bahia08, we
104 enriched the mNGS library for ZIKV sequences using a set of 299 XGen biotinylated

105 lockdown capture probes (IDT Technologies) targeting all ZIKV genomes in the National
106 Center for Biotechnology Information (NCBI) GenBank database, as previously
107 described (14). Enrichment was performed using the XGen lockdown protocol and
108 SeqCap EZ Hybridization and Wash Kit (Roche Molecular Systems) according to the
109 manufacturer's instructions.

110 **Phylogenetic analysis.** Using the MAFFT program in Geneious, all 43 ZIKV
111 genome sequences available in NCBI GenBank as of March 2016 and 13 CHIKV
112 sequences from the East / Central / South African (ECSA) clade were aligned together
113 with 3 ZIKV and 2 CHIKV complete or partial genomes recovered in the current study.
114 Phylogenetic trees were constructed using the neighbor joining algorithm with 1,000
115 bootstrap replicates, followed by refinement using the MrBayes algorithm at default
116 settings in the Geneious software package (Biomatters, Inc.).

117 **Accession Numbers.** NGS reads with human sequences removed have been
118 deposited in the Sequence Read Archive (accession number SRP072069). The 3 ZIKV
119 and 2 CHIKV genome sequences have been deposited in NCBI GenBank (accession
120 numbers KU940224, KU940227, and KU940228 for the ZIKV genomes and KU940225
121 and KU940226 for the CHIKV genomes).

122

123 **RESULTS**

124

125 **Metagenomic next-generation sequencing of ZIKV serum samples**

126 Serum samples were collected from 15 patients within 5 days of symptom onset
127 and at the first visit seen during an ongoing ZIKV outbreak at Aliança Hospital in
128 Salvador, Bahia, Brazil from April 2015 to January 2016 (15). All 15 patients tested
129 positive for ZIKV by RT-PCR and negative for DENV by serology. From 24,063 to
130 6,903,397 million mNGS reads were generated per sample, and reads aligning to ZIKV

131 were identified in 13 of 15 (86.7%) ZIKV PCR-positive samples (Table 1). Two ZIKV
132 PCR-positive samples (BR13 and BR14) were negative for ZIKV reads by mNGS, and
133 both exhibited low viral titers by qRT-PCR (<30 copies / mL and 517 copies / mL,
134 respectively) (Table 1). A log-log plot of ZIKV mNGS reads (in reads per million, or RPM)
135 against viral titer revealed a moderate correlation, with a log R-squared value of 0.73255
136 (Figure 1).

137 Reads aligning to CHIKV were detected in 6 of 15 (40.0%) ZIKV-positive
138 samples. Given the possibility of cross-contamination from a previously unknown high-
139 titer CHIKV sample (Bahia08), the mNGS run was repeated after removing this sample
140 library. However, the repeat run still resulted in detection of CHIKV reads in 5 of 15
141 (33.3%) samples. Since we could not reliably distinguish between mNGS library cross-
142 contamination versus low-level metagenomic detection near the limits of detection for
143 RT-PCR, a co-infection with CHIKV was only considered established if independently
144 confirmed by orthogonal testing using a CHIKV nested RT-PCR (10, 11). Using this
145 criterion (both mNGS and RT-PCR positivity for CHIKV), 2 of 15 (13.3%) ZIKV-positive
146 samples (Bahia08 and Bahia09) were designated as CHIKV/ZIKV co-infections. Aside
147 from ZIKV and CHIKV, apparent co-infections from other viral pathogens associated with
148 acute febrile illness were not detected. Additional viral reads detected in the mNGS data
149 were sparse and were attributed to known commensals (e.g. human pegivirus 1 / GBV-
150 C, papillomaviruses), viruses with non-human hosts (e.g. phage, insect viruses), or
151 laboratory contamination due to detection in unrelated mNGS datasets (e.g. adenovirus,
152 rotavirus, polyomavirus) (Table 2). Notably, no mNGS reads aligning to DENV were
153 detected, and DENV RT-PCR testing of all 15 samples was also negative (Table 1).

154

155 **Clinical presentation of patients with CHIKV/ZIKV co-infection**

156 The first patient of two found to be co-infected with ZIKV and CHIKV (Bahia08)
157 was a 48 year-old woman from Salvador, Brazil, seen in the hospital emergency room
158 (ER) on July 15th, 2015 with 2 days of joint pain involving the elbows, hands, knees, and
159 ankles associated with fever, myalgia, nausea, and headache. She also complained of
160 dysuria, but denied rash or conjunctivitis. Vital signs in the ER revealed a low-grade
161 fever (37.9°C), and physical exam showed diffuse joint pain that made it difficult for her
162 to lift her arms or grasp objects with her hands. Laboratory tests were remarkable only
163 for leukopenia (white blood cell (WBC) count = 1,900 cells/ μ L [normal range 4,500 -
164 10,000]) and thrombocytopenia (platelets = 124,000 cells/ μ L; [normal range 150,000 -
165 400,000]); hemoglobin was 13.4 [normal range 12.0 - 15.5 g/dL]. Dengue IgG, IgM, and
166 NS1 serologies were unreactive. A urinalysis showed 36,500 RBCs and 11,500 WBCs
167 per mL; leukocyte esterase was negative, as was urine culture. The patient was treated
168 with pain medications and discharged home. She returned to the ER 15 and 21 days
169 after the initial visit with persistent neck pain and arthralgias and was discharged from
170 the ER both times on pain medications.

171 The second patient (Bahia09) was a 40 year-old woman presenting April 15th,
172 2015 with a 2-day history of fever, conjunctivitis, myalgia, and pruritic rash. Exam
173 revealed a diffuse rash, conjunctival hyperemia, and a painful posterior cervical lymph
174 node measuring 5 mm. Vital signs were normal. Laboratory tests were remarkable for
175 mild leukopenia (WBC count = 3,930 cells/ μ L, with 39% neutrophils and 43%
176 lymphocytes); hemoglobin and platelet counts were normal at 13.0 g/L and 227,000
177 cells/ μ L, respectively. Dengue serologies were negative. The patient fully recovered 7
178 days after symptom onset.

179

180 **Genome Assembly and Phylogenetic Analysis of ZIKV and CHIKV**

181 We assembled 100% and 71% of the CHIKV genome corresponding to the two
182 co-infected patients Bahia08 and Bahia09, respectively, by mapping the CHIKV mNGS
183 reads to the most closely matched reference genome in NCBI GenBank identified using
184 SURPI. Similarly, 99% of the ZIKV genome from Bahia09 and 100% of the ZIKV
185 genome from third ZIKV patient who was not co-infected (Bahia07) were assembled
186 directly from mNGS reads. To recover 88% of the ZIKV Bahia08 genome, we boosted
187 the number of mNGS reads using ZIKV capture probe enrichment of the metagenomic
188 libraries (16). Bayesian phylogenetic analysis, including all of the 43 publicly available
189 ZIKV genomes in the NCBI GenBank database as of March 2016, positioned the 3
190 newly sequenced ZIKV genomes in a Brazilian subclade corresponding to all of the
191 sequenced strains to date from the ongoing 2015-2016 ZIKV outbreak (Figure 2C).
192 Similarly, the 2 CHIKV genomes were placed within a previously described Brazilian
193 subclade (17) that is an offshoot of the East / Central / South African lineage (2) (Figure
194 2A and B). The 3 ZIKV genomes from Bahia, Brazil, as well as the 2 CHIKV genomes,
195 grouped together into local clusters by phylogenetic analysis.

196

197 **DISCUSSION**

198 We report mosquito-borne ZIKV / CHIKV co-infections in 2 of 15 (13.3%) acutely
199 symptomatic individuals with established ZIKV infection in Bahia state, Brazil. These
200 data suggest that the incidence of arboviral co-infections in an ongoing ZIKV outbreak
201 setting (1) may be higher than previously thought. There have been only three cases of
202 ZIKV co-infections described to date, 2 patients with ZIKV and DENV co-infection in New
203 Caledonia (18) and 1 patient with ZIKV, CHIKV, and DENV co-infection from Colombia
204 (19). Similar to these prior reports, the co-infections in the current study did not appear
205 to result in more severe or fulminant disease requiring hospitalization. However, it is
206 notable that infection by the virus present at higher titer was reflected in the clinical

207 presentation of the two co-infected patients. The first patient (strain Bahia08), with a high
208 serum titer of CHIKV, presented with a prolonged "CHIKV-like" illness characterized by
209 urinary inflammation (20) and prominent arthralgias (2) that persisted for weeks,
210 resulting in repeated ER visits, whereas the second patient (strain Bahia09), with a
211 higher titer of ZIKV, presented with a classic "ZIKV-like" presentation consisting of fever,
212 rash, myalgia, and conjunctivitis (1).

213 An emerging diagnostic approach, mNGS, enables detection of all potential
214 pathogens in clinical samples on the basis of uniquely identifying sequence information
215 (9, 10). As the number of viral reads appears to be positively correlated with viral titer
216 (Figure 1), quantitative or at least semi-quantitative information can potentially be
217 extracted from mNGS data. In addition, the genetic information obtained by sequencing
218 is useful for tracking of viral evolution (21), monitoring the geographic and temporal
219 spread of the outbreak (22), and discovery of new viral lineages circulating in the region
220 (16). As a surveillance tool, mNGS also has the potential to elucidate the spectrum of
221 infection in a local geographic area, and thus guide the development of targeted
222 diagnostics, antimicrobial drugs, and vaccines. Traditionally, barriers to NGS
223 implementation have included high costs, complex instrumentation, and lack of
224 dedicated bioinformatics tools. These barriers are being overcome with the
225 development of rapid computational pipelines for analysis of mNGS data (9, 23, 24),
226 emergence of portable sequencers that can be used in field laboratories and other point-
227 of-care settings (25, 26). The establishment of robust cutoff thresholds for calling
228 positives will also be needed before mNGS can be used routinely for infectious disease
229 diagnosis. In particular, our results show that the concordance between PCR and mNGS
230 or between different PCR assays at borderline titers near the limits of detection, while
231 very good, is not perfect (Table 1). Specifically, mNGS was likely more sensitive for
232 detection of CHIKV than the CHIKV PCR used in the current study, given that 8.6% and

233 9.8% of the viral genome was recovered by mNGS from two CHIKV PCR negative
234 samples, while mNGS was less sensitive than or comparable in sensitivity to the ZIKV
235 PCR assays (Table 1). Such discrepancies between mNGS and PCR at very low viral
236 titers have been previously reported in the other metagenomic studies (27, 28), and can
237 potentially be addressed by formal clinical validation of mNGS assay performance and
238 the use of rigorous negative and positive controls (29).

239 It is now established that ZIKV is the cause of severe fetal complications in
240 pregnancy such as in utero demise and microcephaly (4). In addition, current co-
241 circulation of all 3 mosquito-borne arboviruses in Latin America makes diagnosis based
242 solely on clinical or epidemiological criteria unreliable. In our study, CHIKV co-infection
243 was detected incidentally by mNGS of ZIKV-infected patients, underscoring the potential
244 utility of untargeted mNGS sequencing for differential diagnosis of vector-borne febrile
245 illness and identification of co-infections. The failure to detect other pathogens, such as
246 malaria, by comprehensive mNGS suggests that a multiplex assay confined to arboviral
247 infections (ZIKV, DENV, and CHIKV) may be sufficient for diagnosis and surveillance
248 during the ongoing ZIKV outbreak (30).

249

250

251 **Acknowledgements**

252 We thank multiple researchers worldwide for permission to include their
253 unpublished ZIKV genomes in our analysis. This study was supported in part by National
254 Institutes of Health (NIH) grants R01-HL105704 and R21-AI120977 (CYC), and an
255 award from Abbott Laboratories, Inc. (CYC).

256

257 **Conflict of Interest**

258 C.Y.C. is the director of the UCSF-Abbott Viral Diagnostics and Discovery Center and
259 receives research support from Abbott Laboratories, Inc. The other authors disclose no
260 conflict of interest.
261

262 REFERENCES

263

- 264 1. **Fauci AS, Morens DM.** 2016. Zika Virus in the Americas--Yet Another Arbovirus
265 Threat. *N Engl J Med* **374**:601-604.
- 266 2. **Weaver SC, Lecuit M.** 2015. Chikungunya virus and the global spread of a
267 mosquito-borne disease. *N Engl J Med* **372**:1231-1239.
- 268 3. **Carod-Artal FJ, Wichmann O, Farrar J, Gascon J.** 2013. Neurological
269 complications of dengue virus infection. *Lancet Neurol* **12**:906-919.
- 270 4. **Rasmussen SA, Jamieson DJ, Honein MA, Petersen LR.** 2016. Zika Virus and
271 Birth Defects - Reviewing the Evidence for Causality. *N Engl J Med*
272 doi:10.1056/NEJMSr1604338.
- 273 5. **Cao-Lormeau VM, Blake A, Mons S, Lastere S, Roche C, Vanhomwegen J,
274 Dub T, Baudouin L, Teissier A, Larre P, Vial AL, Decam C, Choumet V,
275 Halstead SK, Willison HJ, Musset L, Manuguerra JC, Despres P, Fournier E,
276 Mallet HP, Musso D, Fontanet A, Neil J, Ghawche F.** 2016. Guillain-Barre
277 Syndrome outbreak associated with Zika virus infection in French Polynesia: a
278 case-control study. *Lancet* doi:10.1016/S0140-6736(16)00562-6.
- 279 6. **Balm MN, Lee CK, Lee HK, Chiu L, Koay ES, Tang JW.** 2012. A diagnostic
280 polymerase chain reaction assay for Zika virus. *J Med Virol* **84**:1501-1505.
- 281 7. **Greninger AL, Messacar K, Dunnebacke T, Naccache SN, Federman S,
282 Bouquet J, Mirsky D, Nomura Y, Yagi S, Glaser C, Vollmer M, Press CA,
283 Klenschmidt-DeMasters BK, Dominguez SR, Chiu CY.** 2015. Clinical
284 metagenomic identification of Balamuthia mandrillaris encephalitis and assembly
285 of the draft genome: the continuing case for reference genome sequencing.
286 *Genome Med* **7**:113.
- 287 8. **Greninger AL, Naccache SN, Messacar K, Clayton A, Yu G, Somasekar S,
288 Federman S, Stryke D, Anderson C, Yagi S, Messenger S, Wadford D, Xia D,
289 Watt JP, Van Haren K, Dominguez SR, Glaser C, Aldrovandi G, Chiu CY.**
290 2015. A novel outbreak enterovirus D68 strain associated with acute flaccid
291 myelitis cases in the USA (2012-14): a retrospective cohort study. *Lancet Infect*
292 *Dis* **15**:671-682.
- 293 9. **Naccache SN, Federman S, Veeraraghavan N, Zaharia M, Lee D, Samayoa
294 E, Bouquet J, Greninger AL, Luk KC, Enge B, Wadford DA, Messenger SL,
295 Genrich GL, Pellegrino K, Grard G, Leroy E, Schneider BS, Fair JN,
296 Martinez MA, Isa P, Crump JA, DeRisi JL, Sittler T, Hackett J, Jr., Miller S,
297 Chiu CY.** 2014. A cloud-compatible bioinformatics pipeline for ultrarapid
298 pathogen identification from next-generation sequencing of clinical samples.
299 *Genome Res* **24**:1180-1192.
- 300 10. **Chiu CY, Bres V, Yu G, Kryzstof D, Naccache SN, Lee D, Pfeil J, Linnen JM,
301 Stramer SL.** 2015. Genomic Assays for Identification of Chikungunya Virus in
302 Blood Donors, Puerto Rico, 2014. *Emerg Infect Dis* **21**:1409-1413.
- 303 11. **Pfeffer M, Linssen B, Parke MD, Kinney RM.** 2002. Specific detection of
304 chikungunya virus using a RT-PCR/nested PCR combination. *J Vet Med B Infect*
305 *Dis Vet Public Health* **49**:49-54.
- 306 12. **Lanciotti RS, Kosoy OL, Laven JJ, Velez JO, Lambert AJ, Johnson AJ,
307 Stanfield SM, Duffy MR.** 2008. Genetic and serologic properties of Zika virus
308 associated with an epidemic, Yap State, Micronesia, 2007. *Emerg Infect Dis*
309 **14**:1232-1239.

- 310 13. **Lanciotti RS, Calisher CH, Gubler DJ, Chang GJ, Vorndam AV.** 1992. Rapid
311 detection and typing of dengue viruses from clinical samples by using reverse
312 transcriptase-polymerase chain reaction. *J Clin Microbiol* **30**:545-551.
- 313 14. **Naccache SN, Thézé J, Sardi SI, Somasekar S, Greninger AL, Bandeira AC,**
314 **Campos GS, Tauro LB, Faria NR, Pybus OG, Chiu CY.** 2016. Distinct Zika
315 virus lineage in Salvador, Bahia, Brazil. *Emerg Infect Dis* (**in press**)
- 316 .
- 317 15. **Campos GS, Bandeira AC, Sardi SI.** 2015. Zika Virus Outbreak, Bahia, Brazil.
318 *Emerg Infect Dis* **21**:1885-1886.
- 319 16. **Naccache S, Theze J, Sardi SI, Somasekar S, Greninger AL, Candeira AC,**
320 **Campos GS, Tauro LB, Faria NR, Pybus OG, Chiu CY.** 2016. Distinct Zika
321 virus lineage in Salvador, Bahia, Brazil. *Emerg Infect Dis* (**in press**).
- 322 17. **Nunes MR, Faria NR, de Vasconcelos JM, Golding N, Kraemer MU, de**
323 **Oliveira LF, Azevedo Rdo S, da Silva DE, da Silva EV, da Silva SP, Carvalho**
324 **VL, Coelho GE, Cruz AC, Rodrigues SG, Vianez JL, Jr., Nunes BT, Cardoso**
325 **JF, Tesh RB, Hay SI, Pybus OG, Vasconcelos PF.** 2015. Emergence and
326 potential for spread of Chikungunya virus in Brazil. *BMC Med* **13**:102.
- 327 18. **Dupont-Rouzeyrol M, O'Connor O, Calvez E, Daures M, John M, Grangeon**
328 **JP, Gourinat AC.** 2015. Co-infection with Zika and dengue viruses in 2 patients,
329 New Caledonia, 2014. *Emerg Infect Dis* **21**:381-382.
- 330 19. **Villamil-Gomez WE, Gonzalez-Camargo O, Rodriguez-Ayubi J, Zapata-**
331 **Serpa D, Rodriguez-Morales AJ.** 2016. Dengue, chikungunya and Zika co-
332 infection in a patient from Colombia. *J Infect Public Health*
333 doi:10.1016/j.jiph.2015.12.002.
- 334 20. **Baishya R, Jain V, Ganpule A, Muthu V, Sabnis RB, Desai MR.** 2010.
335 Urological manifestations of Chikungunya fever: A single centre experience. *Urol*
336 *Ann* **2**:110-113.
- 337 21. **Gire SK, Goba A, Andersen KG, Sealfon RS, Park DJ, Kanneh L, Jalloh S,**
338 **Momoh M, Fullah M, Dudas G, Wohl S, Moses LM, Yozwiak NL, Winnicki S,**
339 **Matranga CB, Malboeuf CM, Qu J, Gladden AD, Schaffner SF, Yang X, Jiang**
340 **PP, Nekoui M, Colubri A, Coomber MR, Fonnies M, Moigboi A, Gbakie M,**
341 **Kamara FK, Tucker V, Konuwa E, Saffa S, Sellu J, Jalloh AA, Kovoma A,**
342 **Koninga J, Mustapha I, Kargbo K, Foday M, Yillah M, Kanneh F, Robert W,**
343 **Massally JL, Chapman SB, Bochicchio J, Murphy C, Nusbaum C, Young S,**
344 **Birren BW, Grant DS, Scheffelin JS, Lander ES, Hapfi C, Gevaio SM, Gnirke**
345 **A, Rambaut A, Garry RF, Khan SH, Sabeti PC.** 2014. Genomic surveillance
346 elucidates Ebola virus origin and transmission during the 2014 outbreak. *Science*
347 **345**:1369-1372.
- 348 22. **Faria NR, Azevedo Rdo S, Kraemer MU, Souza R, Cunha MS, Hill SC, Theze**
349 **J, Bonsall MB, Bowden TA, Rissanen I, Rocco IM, Nogueira JS, Maeda AY,**
350 **Vasami FG, Macedo FL, Suzuki A, Rodrigues SG, Cruz AC, Nunes BT,**
351 **Medeiros DB, Rodrigues DS, Nunes Queiroz AL, da Silva EV, Henriques DF,**
352 **Travassos da Rosa ES, de Oliveira CS, Martins LC, Vasconcelos HB,**
353 **Casseb LM, Simith Dde B, Messina JP, Abade L, Lourenco J, Alcantara LC,**
354 **de Lima MM, Giovanetti M, Hay SI, de Oliveira RS, Lemos Pda S, de Oliveira**
355 **LF, de Lima CP, da Silva SP, de Vasconcelos JM, Franco L, Cardoso JF,**
356 **Vianez-Junior JL, Mir D, Bello G, Delatorre E, Khan K, Creatore M, Coelho**
357 **GE, de Oliveira WK, Tesh R, Pybus OG, Nunes MR, Vasconcelos PF.** 2016.
358 Zika virus in the Americas: Early epidemiological and genetic findings. *Science*
359 **352**:345-349.

- 360 23. **Flygare S, Simmon K, Miller C, Qiao Y, Kennedy B, Di Sera T, Graf EH,**
361 **Tardif KD, Kapusta A, Ryneerson S, Stockmann C, Queen K, Tong S,**
362 **Voelkerding KV, Blaschke A, Byington CL, Jain S, Pavia A, Ampofo K,**
363 **Eilbeck K, Marth G, Yandell M, Schlaberg R.** 2016. Taxonomer: an interactive
364 metagenomics analysis portal for universal pathogen detection and host mRNA
365 expression profiling. *Genome Biol* **17**:111.
- 366 24. **Wood DE, Salzberg SL.** 2014. Kraken: ultrafast metagenomic sequence
367 classification using exact alignments. *Genome Biol* **15**:R46.
- 368 25. **Greninger AL, Naccache SN, Federman S, Yu G, Mbala P, Bres V, Stryke D,**
369 **Bouquet J, Somasekar S, Linnen JM, Dodd R, Mulembakani P, Schneider**
370 **BS, Muyembe-Tamfum JJ, Stramer SL, Chiu CY.** 2015. Rapid metagenomic
371 identification of viral pathogens in clinical samples by real-time nanopore
372 sequencing analysis. *Genome Med* **7**:99.
- 373 26. **Quick J, Loman NJ, Duraffour S, Simpson JT, Severi E, Cowley L, Bore JA,**
374 **Koundouno R, Dudas G, Mikhail A, Ouedraogo N, Afrough B, Bah A, Baum**
375 **JH, Becker-Ziaja B, Boettcher JP, Cabeza-Cabrero M, Camino-Sanchez A,**
376 **Carter LL, Doerrbecker J, Enkirch T, Garcia-Dorival I, Hetzelt N, Hinzmann**
377 **J, Holm T, Kafetzopoulou LE, Koropogui M, Kosgey A, Kuisma E, Logue**
378 **CH, Mazzarelli A, Meisel S, Mertens M, Michel J, Ngabo D, Nitzsche K,**
379 **Pallasch E, Patrono LV, Portmann J, Repits JG, Rickett NY, Sachse A,**
380 **Singethan K, Vitoriano I, Yemanaberhan RL, Zekeng EG, Racine T, Bello A,**
381 **Sall AA, Faye O, Faye O, Magassouba N, Williams CV, Amburgey V, Winona**
382 **L, Davis E, Gerlach J, Washington F, Monteil V, Jourdain M, Bererd M,**
383 **Camara A, Somlare H, Camara A, Gerard M, Bado G, Baillet B, Delaune D,**
384 **Nebie KY, Diarra A, Savane Y, Pallawo RB, Gutierrez GJ, Milhano N, Roger**
385 **I, Williams CJ, Yattara F, Lewandowski K, Taylor J, Rachwal P, Turner DJ,**
386 **Pollakis G, Hiscox JA, Matthews DA, O'Shea MK, Johnston AM, Wilson D,**
387 **Hutley E, Smit E, Di Caro A, Wolfel R, Stoecker K, Fleischmann E, Gabriel**
388 **M, Weller SA, Koivogui L, Diallo B, Keita S, Rambaut A, Formenty P,**
389 **Gunther S, Carroll MW.** 2016. Real-time, portable genome sequencing for
390 Ebola surveillance. *Nature* **530**:228-232.
- 391 27. **Cheval J, Sauvage V, Frangeul L, Dacheux L, Guigon G, Dumey N, Pariente**
392 **K, Rousseaux C, Dorange F, Berthet N, Brisse S, Moszer I, Bourhy H,**
393 **Manuguerra CJ, Lecuit M, Burguiere A, Caro V, Eloit M.** 2011. Evaluation of
394 high-throughput sequencing for identifying known and unknown viruses in
395 biological samples. *J Clin Microbiol* **49**:3268-3275.
- 396 28. **Wylie TN, Wylie KM, Herter BN, Storch GA.** 2015. Enhanced virome
397 sequencing using targeted sequence capture. *Genome Res* **25**:1910-1920.
- 398 29. **Goldberg B, Sichtig H, Geyer C, Ledebouer N, Weinstock GM.** 2015. Making
399 the Leap from Research Laboratory to Clinic: Challenges and Opportunities for
400 Next-Generation Sequencing in Infectious Disease Diagnostics. *MBio* **6**:e01888-
401 01815.
- 402 30. **CDC.** 2016. Revised diagnostic testing for Zika, chikungunya, and dengue
403 viruses in US Public Health Laboratories.
404 <https://http://www.cdc.gov/zika/pdfs/denvchikvzikkv-testing-algorithm.pdf>.
405 Accessed Feb 24.
- 406
- 407

408 **Table 1. ZIKV and CHIKV testing of 15 PCR-positive ZIKV cases in Bahia, Brazil**
409 **from April 2015 to January 2016.**

410 **Table 2. Reads in the mNGS data corresponding to other viruses aside from**
411 **CHIKV and ZIKV.**

412

413 **Figure 1. Log-log plot of detected ZIKV reads against viral titer.** The number of
414 mNGS reads is normalized to reads per million (RPM) of raw reads sequenced. A power
415 trendline is fitted to the data, showing an R^2 correlation of 0.73255.

416

417 **Figure 2. Whole-genome phylogeny of CHIKV and ZIKV. (A)** Phylogeny of all 314
418 CHIKV genomes available in NCBI GenBank as of March 2016 and 2 new complete or
419 partial genomes from the current study. The 3 major lineages of CHIKV are shown in
420 different colors. **(B)** Phylogeny of 14 genomes corresponding to a local cluster within the
421 ECSA (East / Central /South African) clade outlined with a dotted box in **(A)**. An ECSA
422 CHIKV isolate located outside of the cluster, HM045809, is included as an outgroup. **(C)**
423 Phylogeny of all 44 ZIKV genomes available in NCBI GenBank as of March 2016 and 3
424 new complete or partial genomes from the current study. Genomes corresponding to the
425 2015-2016 ZIKV outbreak in Latin America are highlighted with a light orange
426 background. The asterisks denote genomes corresponding to ZIKV cases in returning
427 travelers. New CHIKV and ZIKV genomes sequenced in the current study are
428 highlighted in boldface red, with the percent genome recovery provided in parentheses.
429 Branch lengths are drawn proportionally to the number of nucleotide substitutions per
430 position, and support values are shown for each node.

431

432

Sample	Testing before mNGS		Metagenomic next-generation sequencing (mNGS)									Testing after mNGS			
	ZIKV RT-PCR*	DENV Ab	# of raw reads	# of ZIKV reads	% ZIKV reads	ZIKV mNGS (run1/run2)	% ZIKV coverage	# of CHIKV reads	% CHIKV reads	CHIKV mNGS (run1/run2)	% CHIKV coverage	CHIKV RT-PCR	ZIKV qRT-PCR**	ZIKV viral load (copies/mL)	DENV RT-PCR
Bahia01	+	-	3,507,376	103	0.003	+ / +	34.1%	0	0	- / -	0.0%	-	+	1,042	-
Bahia02	+	-	3,668,673	129	0.003	+ / +	39.5%	0	0	- / -	0.0%	-	+	4,086	-
Bahia03	+	-	24,063	2	0.008	+ / +	1.3%	0	0	- / -	0.0%	-	+	3,272	-
Bahia04	+	-	3,060,229	14	0.0005	+ / +	9.6%	0	0	- / -	0.0%	-	+	1,464	-
Bahia05	+	-	3,501,316	19	0.0005	+ / +	11.8%	0	0	- / -	0.0%	-	+	1,091	-
Bahia06	+	-	2,576,002	11	0.0004	+ / +	5.4%	4	0.0002	+ / +	1.1%	-	-	<31	-
Bahia07	+	-	6,903,397	281,099	4.1	+	100.0%	0	0	- / -	0.0%	-	+	9.00E+08	-
Bahia08	+	-	1,094,355	55	0.005	+	35.1%	252,649	23.1	+ / +	100.0%	+	+	2,470	-
Bahia09	+	-	743,266	719	0.1	+	97.6%	84	0.01	+ / +	49.1%	+	+	23,121	-
Bahia10	+	-	2,482,665	22	0.0009	+ / +	5.7%	0	0	- / -	0.0%	-	-	<31	-
Bahia11	+	-	2,384,416	234	0.01	+ / +	40.9%	37	0.002	+ / +	8.6%	-	+	3,981	-
Bahia12	+	-	3,712,405	44	0.001	+ / +	21.3%	23	0.0006	+ / +	9.8%	-	+	1,327	-
Bahia13	+	-	2,556,556	0	0	- / -	0.0%	1	0	+ / -	1.4%	-	-	<31	-
Bahia14	+	-	3,658,143	0	0	- / -	0.0%	0	0	- / -	0.0%	-	+	517	-
Bahia15	+	-	2,848,486	17	0.001	+ / +	7.9%	0	0	- / -	0.0%	-	-	<31	-


*RT-PCR assay using primers and conditions from Balm, et al., 2012



**SYBR-Green qRT-PCR assay using PCR primers targeting the envelope gene (ZIKV-1086/ZIKV-1162) and conditions from Lanciotti, et al., 2008

Viral species or genus	# of reads	# of samples	Explanation
<i>Human mastadenovirus A</i>	1	1	suspected lab contaminant**
<i>Human pegivirus 1 (GBV-C)</i>	1,710	1	viral blood commensal
<i>Papillomavirus</i>	1-12	5	viral skin commensal
<i>Merkel cell polyomavirus</i>	1	3	unclear clinical significance; suspected lab contaminant**
<i>WU polyomavirus</i>	3	1	unclear clinical significance; suspected lab contaminant**
<i>Rotavirus</i>	1-4	5	suspected lab contaminant**
<i>Enterovirus D68</i>	1-3	2	suspected lab contaminant (Greninger, et al., 2014, <i>Lancet Infectious Diseases</i>)**
<i>Molluscum contagiosum virus</i>	1	1	suspected lab contaminant**

*viruses with nonhuman hosts (e.g. insect viruses, phages, mouse gammaretroviruses) are not reported

**detected in other unrelated sequencing datasets processed in the research laboratory at the same time





Downloaded from <http://jcm.asm.org/> on July 29, 2016 by guest